Marinus Pharmaceuticals

Marinus Pharmaceuticals EBITDA

Delisted

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Marinus Pharmaceuticals (MRNS) as of Nov 12, 2026 is -134.77 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -8.11 M USD — a change of 1,561.93% (lower).

EBITDA

-134.77 MUSD

YoY

1,561.93%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Marinus Pharmaceuticals is 2023 -134.77 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Marinus Pharmaceuticals was 2022 -8.11 M USD. It decreases by 1,561.93% lower compared to the previous year.

The Marinus Pharmaceuticals EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2016
-28.31 M USD
Jan 1, 2017
-19.04 M USD
Jan 1, 2018
-37.18 M USD
Jan 1, 2019
-54.42 M USD
Jan 1, 2020
-67.94 M USD
Jan 1, 2021
-96.27 M USD
Jan 1, 2022
-8.11 M USD
Jan 1, 2023
-134.77 M USD
The Marinus Pharmaceuticals EBITDA history
YEAREBITDAYoY
-134.77 MUSD+1,561.93%
-8.11 MUSD-91.58%
-96.27 MUSD+41.71%
-67.94 MUSD+24.83%
-54.42 MUSD+46.38%
-37.18 MUSD+95.24%
-19.04 MUSD-32.73%
-28.31 MUSD+15.86%
-24.43 MUSD+104.97%
-11.92 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Marinus Pharmaceuticals Stock analysis

What does Marinus Pharmaceuticals do? Marinus Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of novel therapeutics for various neurological disorders. The company, headquartered in Radnor, Pennsylvania, USA, was founded in 2003 and has been listed on NASDAQ since 2012. Marinus Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Marinus Pharmaceuticals stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Marinus Pharmaceuticals is -134.77 M USD in 2023.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Marinus Pharmaceuticals changed from -8.11 M USD to -134.77 M USD, representing a 1,561.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Marinus Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Marinus Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Marinus Pharmaceuticals

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Marinus Pharmaceuticals